Prelude Capital Management’s Instil Bio TIL Stock Holding History

Prelude Capital Management’s Portfolio TIL Stock Details TIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,300	Closed	-$84.9K	–	1529
2026 Q1	$84.9K	Buy	+10,300	New	+$83.6K	0.01%	1077

Other funds holding TIL

CVV

Curative Ventures V Dallas, Texas $14.6M AUM 63.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Prelude Capital Management's TIL Position: Q2 2026 in Review

Prelude Capital Management sold out of Instil Bio (TIL) in Q2 2026, closing a stake of 10,300 shares — an estimated $84.9K sold.

Prelude Capital Management first reported a position in TIL in Q1 2026 and held it in 1 quarter. The position peaked at $84.9K in Q1 2026. 26 funds tracked by Wall St. Rank hold TIL as of Q2 2026.

Prelude Capital Management reported no remaining Instil Bio position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 10,300 Instil Bio shares in Q2 2026, an estimated $84.9K.
Prelude Capital Management first reported a position in Instil Bio in Q1 2026 and held it in 1 quarter.
Prelude Capital Management's Instil Bio position peaked at $84.9K in Q1 2026.
26 funds tracked by Wall St. Rank held Instil Bio as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.